These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 2113117)

  • 1. [Prostacyclin and metabolite assay and the clinical significance].
    Suzuki H; Fujimoto N; Shio H
    Nihon Rinsho; 1990 Feb; 48 Suppl():193-6. PubMed ID: 2113117
    [No Abstract]   [Full Text] [Related]  

  • 2. Development of a radioimmunoassay for the measurement of prostacyclin metabolites in unextracted plasma.
    McLaren M; Belch JJ; Forbes CD
    Adv Prostaglandin Thromboxane Leukot Res; 1985; 13():41-2. PubMed ID: 3159227
    [No Abstract]   [Full Text] [Related]  

  • 3. Prostacyclin concentrations in cord blood and in the newborn.
    Jacqz EM; Barrow SE; Dollery CT
    Pediatrics; 1985 Dec; 76(6):954-7. PubMed ID: 3906549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostacyclin is not a circulating hormone in man.
    Blair IA; Barrow SE; Waddell KA; Lewis PJ; Dollery CT
    Prostaglandins; 1982 Apr; 23(4):579-89. PubMed ID: 7051184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism of prostacyclin and 6-keto-prostaglandin F1 alpha in man.
    Rosenkranz B; Fischer C; Reimann I; Weimer KE; Beck G; Frölich JC
    Artery; 1980; 8(1):18-22. PubMed ID: 7000039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of the major metabolite of prostacyclin and 6-ketoprostaglandin F1 alpha in man.
    Rosenkranz B; Fischer C; Reimann I; Weimer KE; Beck G; FRölich JC
    Biochim Biophys Acta; 1980 Aug; 619(2):207-13. PubMed ID: 6996737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Problems of assessment of prostacyclin formation in vivo.
    Rosenkranz B; Frölich JC
    Prostaglandins; 1984 May; 27(5):655-7. PubMed ID: 6379755
    [No Abstract]   [Full Text] [Related]  

  • 8. Quantitative analysis of 6-keto-prostaglandin F1 alpha in biological fluids.
    Morita I; Murota S; Miyatake T; Ohno T; Suzuki M
    Adv Prostaglandin Thromboxane Leukot Res; 1985; 15():95-7. PubMed ID: 2936209
    [No Abstract]   [Full Text] [Related]  

  • 9. [Effect of saralasin on the activity of the renin-angiotensin-aldosterone system, sympathetic-adrenal system and the level of the 6-keto-PGF1 alpha metabolite of prostacyclin in patients with primary arterial hypertension].
    Bar-Andziak E; Ignatowska-Switalska H; Wocial B; Kabat M; Makowiecka-Cieśla M; Cybulska I; Sznajderman M
    Kardiol Pol; 1985; 28(7):481-8. PubMed ID: 3910904
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of eicosapentaenoic acid (EPA) on prostacyclin production in diabetics: GC/MS analysis of PGI2 and PGI3 levels.
    Nishikawa M; Hishinuma T; Nagata K; Koseki Y; Suzuki K; Mizugaki M
    Methods Find Exp Clin Pharmacol; 1997; 19(6):429-33. PubMed ID: 9385592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measurement of prostacyclin metabolites.
    Belch JJ; Greer I; McLaren M; Walker J; Forbes CD
    Lancet; 1983 Dec 24-31; 2(8365-66):1504. PubMed ID: 6140597
    [No Abstract]   [Full Text] [Related]  

  • 12. Release of adenosine and prostacyclin from ischemic human hearts.
    Edlund A; Berglund B; Kaijser L; Patrono C; Sollevi A; van Dorne D; Wennmalm A
    Adv Prostaglandin Thromboxane Leukot Res; 1983; 11():365-70. PubMed ID: 6221547
    [No Abstract]   [Full Text] [Related]  

  • 13. Prostacyclin and thromboxane levels.
    Williams GA; Reeser FH
    Ophthalmology; 1983 Jul; 90(7):856-7. PubMed ID: 6353310
    [No Abstract]   [Full Text] [Related]  

  • 14. Prostacyclin in systemic lupus and anticardiolipin syndrome.
    Asherson RA; Harris EN; Hughes GR; Ritter JM; Barrow SE; Jones M
    Ann Rheum Dis; 1987 May; 46(5):422-3. PubMed ID: 3296970
    [No Abstract]   [Full Text] [Related]  

  • 15. Decreased prostacyclin levels in sickle cell disease.
    Longenecker GL; Mankad V
    Pediatrics; 1983 May; 71(5):860-1. PubMed ID: 6340054
    [No Abstract]   [Full Text] [Related]  

  • 16. Metabolic disposition of prostacyclin in humans.
    Brash AR; Jackson EK; Saggese CA; Lawson JA; Oates JA; FitzGerald GA
    J Pharmacol Exp Ther; 1983 Jul; 226(1):78-87. PubMed ID: 6345756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet microaggregates and release of endogenous prostacyclin during the initial phase of haemodialysis.
    Leithner C; Sinzinger H; Silberbauer K; Stummvoll HK
    Proc Eur Dial Transplant Assoc; 1981; 18():122-5. PubMed ID: 7036146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo formation of prostacyclin and thromboxane A2 at the site of platelet-vascular interaction in humans.
    Nowak J; FitzGerald GA
    Adv Prostaglandin Thromboxane Leukot Res; 1987; 17A():208-11. PubMed ID: 2959050
    [No Abstract]   [Full Text] [Related]  

  • 19. Factors affecting the production of prostacyclin in man.
    Hensby CN; Webster J; Lewis PJ; Crowley KT; Dollery CT
    Prog Lipid Res; 1981; 20():565-7. PubMed ID: 7043484
    [No Abstract]   [Full Text] [Related]  

  • 20. Aspirin and prostacyclin synthesis in humans.
    Vesterqvist O; Gréen K
    Circulation; 1990 Jan; 81(1):392-4. PubMed ID: 2105171
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.